CA AB1887

Prohibits health care service plans and health insurers from imposing prior authorization, step therapy, or other utilization review for FDA-approved drugs prescribed to treat rare diseases when a prescribing provider determines the drug is medically necessary

Applies to health plan contracts and insurance policies issued, amended, or renewed on or after January 1, 2027

Defines "rare disease" as a disease affecting fewer than 200,000 people in the United States

Exception allows utilization review requirements if a biosimilar, interchangeable biologic, or generic version of the prescribed drug is available

Does not apply to Medi-Cal managed care contracts with the State Department of Health Care Services